# Docetaxel in Non Small Cell Lung Cancer (NSCLC)

> **NCT00432315** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 80 (actual)

## Conditions studied

- Carcinoma, Squamous Cell

## Interventions

- **DRUG:** Docetaxel + CDDP
- **DRUG:** docetaxel + CDDP

## Key facts

- **NCT ID:** NCT00432315
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2010-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00432315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00432315, "Docetaxel in Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-09-12 from https://api.ai-analytics.org/clinical/NCT00432315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*